DORUCIN is an anthracycline chemotherapeutic agent that works by intercalating DNA strands, inhibiting nucleic acid synthesis, and causing apoptosis in rapidly dividing cancer cells.
Recommended for:
Breast cancer, ovarian cancer, stomach cancer
Soft tissue and bone sarcomas
Hodgkin’s and non-Hodgkin’s lymphomas
Acute leukaemias
Administered only under specialist supervision in oncology settings
Breast carcinoma
Lymphomas (Hodgkin and non-Hodgkin)
Osteosarcoma and soft tissue sarcomas
Ovarian and gastric cancers
Acute leukaemias
Administered via intravenous infusion under hospital supervision. Dosage and cycle duration vary based on the type of cancer, treatment protocol, and patient's clinical condition.
Contraindications:
Severe cardiac impairment
Pregnancy and breastfeeding
Known allergy to doxorubicin
Side effects:
Bone marrow suppression, anaemia
Cardiotoxicity, arrhythmia
Alopecia (hair loss)
Nausea, vomiting, stomatitis
